Vaxart Adjusts BARDA Funding After COVID-19 Trial Scope Reduction
Event summary
- Vaxart secures $345M in BARDA funding after a $116M reduction due to a 50% participant drop in its COVID-19 oral pill vaccine trial.
- $29M released for completing the trial and exploratory analyses, enabling deeper data evaluation.
- 12-month data from the 400-participant Sentinel Cohort expected soon; main cohort data due in H1 2027.
- Funding supports Project NextGen, a BARDA-NIAID initiative to accelerate next-gen COVID-19 vaccines.
The big picture
Vaxart's funding adjustment reflects a strategic pivot following BARDA's partial termination of participant enrollment, aligning with broader industry trends toward streamlined clinical trials and cost-efficient development. The focus on oral vaccines positions Vaxart in the growing segment of needle-free immunization technologies, though its success hinges on demonstrating efficacy against established competitors.
What we're watching
- Data Interpretation
- How the deeper analytics from the trial data will impact the efficacy and safety conclusions of Vaxart's oral pill vaccine.
- Regulatory Pathway
- Whether the adjusted funding and participant count will affect BARDA or FDA approval timelines for the vaccine.
- Market Positioning
- The pace at which Vaxart can leverage this data to differentiate itself in the competitive COVID-19 vaccine market.
Related topics